PUMA BIOTECHNOLOGY, INC. - 8-K Filing
Puma Biotechnology reports Q3 2026 net product revenue of $54.1 million and raises full-year 2026 net income guidance to $20–$22 million. (Items: 2.02 shall not be incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of)
Tickers: $PBYI